3839-19-8

Basic information

• Product Name: 4-CYANO-1-NAPHTHOIC ACID
• Synonyms: 4-CYANO-1-NAPHTHOIC ACID;4-Cyano-1-Naphthoic Acid 4cyano1naphthoic acid
• CAS NO: 3839-19-8
• Molecular Formula: C₁₂H₇NO₂
• Molecular Weight: 197.19
• Mol File: 3839-19-8.mol

Chemical Properties

• Boiling Point: 445.682 °C at 760 mmHg
• Flash Point: 223.341 °C
• Appearance: /
• Density: 1.36 g/cm³
• CAS DataBase Reference: 4-CYANO-1-NAPHTHOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CYANO-1-NAPHTHOIC ACID(3839-19-8)
• EPA Substance Registry System: 4-CYANO-1-NAPHTHOIC ACID(3839-19-8)

Safety Data

• Hazardous Substances Data: 3839-19-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-CYANO-1-NAPHTHOIC ACID serves as a fundamental building block in organic synthesis, contributing to the creation of a diverse range of chemical compounds.
Used as a Pharmaceutical Precursor:
In the pharmaceutical industry, 4-CYANO-1-NAPHTHOIC ACID is utilized as a precursor for the production of various drugs, underpinning its importance in medicinal chemistry.
Used in Agrochemical Production:
4-CYANO-1-NAPHTHOIC ACID also plays a role in the agrochemical sector, where it is employed as a precursor to develop different agrochemicals, supporting agricultural productivity and pest control.
Used as a Dye Intermediate:
4-CYANO-1-NAPHTHOIC ACID is harnessed in the dye industry as an intermediate, facilitating the synthesis of dyes with specific color characteristics.
Used in Textile and Plastics Industry:
In the manufacture of optical brightening agents, 4-CYANO-1-NAPHTHOIC ACID is used to enhance the appearance of textiles and plastics, improving their visual appeal and brightness.

Upstream product

• 35615-97-5 4-bromo-naphthalene-1-carboxylic acid methyl ester 
• 41014-20-4 4-bromomethyl-1-naphthonitrile 
• 36062-93-8 1-cyano-4-methylnaphthalene 
• 87700-65-0 4-bromo-1-naphthoic acid chloride 
• 16650-55-8 4-bromonaphthalene-1-carboxylic acid 
• 83-53-4 1,4-dibromonaphthalene 
• 39088-39-6 methyl 4-cyano-1-naphthoate 
• 62855-39-4 4-cyanonaphthalene-1-carboxyaldehyde 

Relevant articles and documents

AMINOETHANOL DERIVATIVES

The present invention provides a pharmaceutical agent having cholesteryl ester transfer protein inhibitory action and useful as a blood lipid lowering agent and the like. The present invention relates to a compound represented by the formula wherein Ar1 is an aromatic ring group optionally having substituents, Ar2 is an aromatic ring group having substituents, OR'' is an optionally protected hydroxyl group, R is an acyl group, R' is a hydrogen atom or a hydrocarbon group optionally having substituents, or a salt thereof, and a pharmaceutical composition containing a compound of the formula (I) or a salt thereof or a prodrug thereof.

N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS

A compound of formula I wherein: R is alkyl; R1 is optionally substituted phenyl 2-oxo-tetrahydro-1(2H)-pyrimidinyl, or 2-oxo-1-piperidinyl; R2 is hydrogen, alkoxy, alkanoyloxy, alkoxycarbonyl, alkanoylamino, acyl, alkyl, carbamoyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl where the alkyl groups are the same or different, hydroxy, thioacyl, thiocarbamoyl, N-alkylthiocarbamoyl, or N,N-dialkylthiocarbamoyl where the alkyl groups are the same or different. X1 and X2 are independently hydrogen or halo, provided that at least one of X1 or X2 is halo; and R3, R4, R5 and R6 are independently hydrogen, cyano, nitro, trifluoromethoxy, trifluoromethyl, or alkylsulfonyl are antagonists of at least one tachykinin receptor and are useful in the treatment of depression, anxiety, asthma, pain, inflammation, urinary incontinence and other disease conditions. Process for their preparation are described, as are compositions containing them and their use.

Discovery of novel, orally active dual NK1/NK2 antagonists

Exploration of the SAR around selective NK2 antagonists, SR48968 and ZD7944, led to the discovery that naphth-1-amide analogues provide potent dual NK1 and NK2 antagonists. ZD6021 inhibited binding of [3H]-NKA or [3H]-SP to human NK1 and NK2 receptors, with high-affinity (Ki=0.12 and 0.62 nM, respectively). In functional assays ZD6021 had, at 10-7 M, in human pulmonary artery pKB=8.9 and in human bronchus pKB=7.3, for NK1 and NK2, respectively. Oral administration of ZD6021 to guinea pigs dose-dependently attenuated ASMSP induced extravasation of plasma proteins, ED50=0.5 mg/kg, and NK2 mediated bronchoconstriction, ED50=13 mg/kg.

Acid-base properties of substituted naphthoic acids in nonaqueous media

Thirteen substituted 1-naphthoic acids have been prepared and their dissociation constants, along with those of twenty-five substituted 2-naphthoic acids, have been measured potentiometrically in methanol, N,N-dimethylformamide, pyridine, and acetonitrile. The pKHA values obtained have been treated by linear regression using four sets of substituent constants. The experimental data have also been interpreted by statistical methods using latent variables. The first latent variable calculated by these methods can be used as a new set of substituent constants for describing substituent effects in naphthalene skeleton.